Stocks and InvestingStocks and Investing
Mon, February 8, 2021
Sat, February 6, 2021
Fri, February 5, 2021
Thu, February 4, 2021

Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $351 on, Feb 4th, 2021


Published on 2024-10-27 15:30:30 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $352 to $351 on, Feb 4th, 2021.

Matthew has made no other calls on BIIB in the last 4 months.



There are 8 other peers that have a rating on BIIB. Out of the 8 peers that are also analyzing BIIB, 6 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $249 on, Thursday, November 19th, 2020
  • Phil Nadeau of "Cowen & Co." Downgraded from Buy to Hold and Held Target at $215 on, Monday, November 9th, 2020
  • Colin Bristow of "UBS" Initiated at Hold and Held Target at $268 on, Wednesday, October 28th, 2020
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $282 on, Tuesday, October 27th, 2020
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $244 on, Thursday, October 22nd, 2020
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Geoff Meacham of "B of A Securities" Downgraded from Hold to Sell and Held Target at $240 on, Monday, November 9th, 2020
  • Steve Chesney of "Atlantic Equities" Downgraded from Hold to Sell and Held Target at $175 on, Monday, November 9th, 2020